Ausgabe 1-2/2014
Inhalt (8 Artikel)
Open Access
Original Research
One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age
Hans-Peter Schwarz, Dorota Birkholz-Walerzak, Mieczyslaw Szalecki, Mieczyslaw Walczak, Corina Galesanu, David Metreveli, Jasmin Khan-Boluki, Ellen Schuck
Open Access
Original Research
Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening
Brigitte Siani, Katharina Willimann, Sandra Wymann, Adriano A. Marques, Eleonora Widmer
Open Access
Original Research
Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
Nazia Rashid, Paul Saenger, Yi-Lin Wu, Heike Woehling, Matthew Frankel, Fima Lifshitz, Michael Muenzberg, Robert Rapaport
Open Access
Original Research
Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency
Jagdev Sidhu, Mikhail Rojavin, Marc Pfister, Jonathan Edelman
Open Access
Original Research
Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting
Gert-Jan Braunstahl, Janice Canvin, Guy Peachey, Chien-Wei Chen, Panayiotis Georgiou
Open Access
Commentary
To the Editor; A Commentary on “Switching From Originator to Biosimilar Human Growth Hormone Using a Dialogue Teamwork: Single-Center Experience From Sweden”
Mats Ekelund, Christopher Bidad, Roy Gomez
Open Access
Case Report
Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures
Fumio Fukuda, Naoaki Kurinomaru, Akihiko Hijioka
Open Access
Erratum
Erratum to: Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
Nazia Rashid, Paul Saenger, Yi-Lin Wu, Heike Woehling, Matthew Frankel, Fima Lifshitz, Michael Muenzberg, Robert Rapaport